Haemadipsa yanyuanensis Bdellin Expansion
Lineage-specific 8.7-25-fold expansion of bdellin protease-inhibitor gene family in H. yanyuanensis genome (Lin 2025) — candidate driver of terrestrial-blood-feeding adaptation.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Lineage-specific 8.7-25-fold expansion of bdellin protease-inhibitor gene family in H. yanyuanensis genome (Lin 2025) — candidate driver of terrestrial-blood-feeding adaptation.
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
Clinical translation limit
This gene-family expansion is identified at the genome / transcriptome level only. Functional activity has not been demonstrated for the individual paralogs. No FDA-approved derivative exists; H. yanyuanensis is not the FDA-cleared K040187 medicinal leech species.
Molecular Profile
- Category
- Proteinase Inhibitor
- Evidence tier
- Preclinical
- Source species
- Haemadipsa yanyuanensis
- Discovered
- 2025 · Lin Y et al.
Biological Targets
- → serine proteases (trypsin, plasmin) — predicted by bdellin homology
Key Citations
- Lin Y et al. (2025), BMC Genomics · PMID 41469844
External Resources
Related Proteinase Inhibitor Compounds
Hirustasin
Serine proteinase inhibitor targeting tissue kallikrein — anti-inflammatory pathway.
Eglin C
Potent inhibitor of human leukocyte elastase and cathepsin G — anti-inflammatory protein widely used as research tool.
Bdellin B3
Kazal-type proteinase inhibitor targeting trypsin and plasmin — modulates inflammatory cascade.
LDTI (Leech-Derived Tryptase Inhibitor)
Selective inhibitor of human mast cell tryptase — anti-inflammatory pathway.